Skip to main content
Fig. 1 | Trials

Fig. 1

From: Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial

Fig. 1

Flowchart of this trial. The patients enrolled in the control group will be treated with the conventionally recommended dose of irinotecan without UGT1A1 genotyping in advance. The patients enrolled in the study group will be divided further into three subgroups according to their UGT1A1 genotypes; irinotecan dose escalation will be based on UGT1A1 genotyping

Back to article page

Trials

ISSN: 1745-6215